Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

1.47
+0.00200.14%
Volume:916.03K
Turnover:1.39M
Market Cap:615.30M
PE:-7.78
High:1.57
Open:1.52
Low:1.47
Close:1.47
52wk High:1.83
52wk Low:0.2836
Shares:418.00M
Float Shares:239.00M
Volume Ratio:1.77
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1891
EPS(LYR):-0.6262
ROE:-45.92%
ROA:-12.94%
PB:5.12
PE(LYR):-2.35

Loading ...

Lexicon Pharmaceuticals Director Raymond Debbane Acquires Common Shares

Reuters
·
Yesterday

Lexicon Pharmaceuticals Director Raymond Debbane Acquires Common Shares

Reuters
·
Feb 19

Lexicon Pharmaceuticals Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Feb 18

Lexicon Pharmaceuticals Files Initial Beneficial Ownership Statement for Avicenna Life Sci Master Fund

Reuters
·
Feb 13

Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing

TIPRANKS
·
Feb 03

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

Reuters
·
Jan 30

BRIEF-Lexicon Announces Pricing Of Approximately $94.6 Million Public Offering At $1.30 Per Share

Reuters
·
Jan 30

Lexicon Pharmaceuticals Inc - Shares Offered at $1.30 per Share

THOMSON REUTERS
·
Jan 30

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THOMSON REUTERS
·
Jan 30

BUZZ-Lexicon Pharma slides after stock offering unveil

Reuters
·
Jan 30

Lexicon announces common stock offering, no amount given

TIPRANKS
·
Jan 30

Lexicon Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jan 30

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

GlobeNewswire
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies

Reuters
·
Jan 21

BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous

Reuters
·
Jan 21

BUZZ-Lexicon rises as FDA clears late‑stage test of diabetic nerve‑pain drug

Reuters
·
Jan 21

Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Neuropathic Pain

Reuters
·
Jan 21

Lexicon Pharmaceuticals Inc - FDA Raised No Objections to Advancement of Pilavapadin Into Phase 3 Development

THOMSON REUTERS
·
Jan 21

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

THOMSON REUTERS
·
Jan 21

Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target

TIPRANKS
·
Jan 21